The role of microRNA-133b and its target gene FSCN1 in gastric cancer by unknown
Guo et al. Journal of Experimental & Clinical Cancer Research 2014, 33:99
http://www.jeccr.com/content/33/1/99RESEARCH Open AccessThe role of microRNA-133b and its target gene
FSCN1 in gastric cancer
Lihua Guo1,2†, Hua Bai3†, Dongling Zou4†, Tao Hong2, Jie Liu1, Jiaqiang Huang2, Pengfei He5, Qi Zhou4*
and Jinsheng He2*Abstract
Background: Increasing evidences have documented that microRNAs (miRNAs) act as oncogenes or tumor
suppressors in gastric cancer (GC). In this study, we aimed to investigate the expression of miR-133b in a large
number of GC samples and elucidate its role in GC carcinogenesis and the detailed mechanism.
Methods: We used Taqman probe stem-loop real-time PCR to accurately measure the levels of miR-133b in 100
pairs of gastric cancer tissues and the adjacent non-neoplastic tissues. miR-133b mimics were overexpressed in GC
cell lines, miR-133b inhibitors were also introduced in GES cells to investigate its role on regulating cell proliferation,
cell migration and cell invasion. The target of miR-133b was identified by luciferase reporter assay and western blot.
Fascin actin-bundling protein 1 (FSCN1) siRNA was used to achieve the knockdown of FSCN1 in GC cells and to
investigate its role on modulating GC cell proliferation and invasion.
Results: miR-133b was significantly down-regulated in GC cell lines and in GC tissues compared with adjacent
normal tissues. Moreover, lower-level of miR-133b was also associated with venous invasion and a more aggressive
tumor phenotype. Re-introduction of miR-133b in GC cells can inhibit cell proliferation, cell migration and invasion.
In contrary, knockdown of miR-133b in GES cells can promote cell proliferation and invasion. Further investigation
indicated that miR-133b targeted FSCN1 in GC cells and knockdown of FSCN1 can also inhibit GC cell growth
and invasion.
Conclusion: Our findings demonstrated that miR-133b was significantly down-regulated in GC tissues and exerted
its tumor suppressor role in GC cells. The investigation of the detailed mechanism showed that miR-133b directly
targeted FSCN1 which functioned as an oncogenic gene in GC cells. These results suggested that miR-133b can be
developed as a new diagnostic marker or therapeutic target for GC.
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Gastric cancer is the second most common cause of
cancer-related death in the world. Diverse treatment strat-
egies including surgery, chemotherapy and radiotherapy
can relieve the pain and lessen the possibility of systemic
metastasis. However, the overall therapeutic activity for
advanced disease remains poor [1]. To discover and iden-
tify new biomarkers for earlier stages of GC or specific* Correspondence: qizhou9128@163.com; jshhe@bjtu.edu.cn
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unless otherwise stated.biomarkers for different individuals is urgently required
for early detection of cancer and individualized therapies.
Recently, the roles of microRNAs (miRNAs) as potential
biomarkers and therapy targets have been widely investi-
gated in many kinds of cancers.
MiRNAs are endogenous small non-coding RNA
molecules, which function in transcriptional and post-
transcriptional regulation of gene expression. Accumulat-
ing evidence demonstrate that miRNAs play important
roles in a variety of biological processes and the deregula-
tion of miRNAs is involved in many diseases [2,3]. Nu-
merous studies have documented that miRNAs acted as
oncogenes or tumor suppressors in diverse cancers, such
as lung, breast, hepatic, pancreatic cancer and gastric. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.jeccr.com/content/33/1/99cancer [4-11]. Currently, the aberrant expression of many
miRNAs has been observed in GC. For example, miR-21,
miR-124, miR-125b, miR-221-222 cluster, miR-106b-25
cluster have been shown to contribute to gastric carcino-
genesis by changing the cell cycle, cell apoptosis, cell mi-
gration and invasion through targeting the relative genes
[12,13]. In addition, a lot of miRNAs, especially circulating
miRNAs, have been shown to be associated with tumor
stages or patient survival, and might be developed as
potential biomarkers for GC diagnosis [14]. Therefore, ex-
ploring the aberrant expression pattern of miRNAs and
the roles of miRNAs in GC will be benefit to understand
the mechanism of GC carcinogenesis and develop new
methods for GC diagnosis and therapy.
miR-133b, which is initially considered to be a
muscle-specific miRNA [15,16], has been reported to be
deregulated in many kinds of cancer [17-22]. The down-
regulation of miR-133b in gastric cancer has also been
reported by several groups [23,24]. Recently, miR-133b
is found to negatively regulate FGFR1 in gastric cancer
and might act as a tumor suppressor in GC [25]. How-
ever, in these studies, the expression of miR-133b was
detected only in a small number of GC tissues or just
in the GC cell lines. The expression of miR-133b in a
large number of clinical samples was not determined.
miR-133b has been reported to directly target oncogenic
Fascin actin-bundling protein 1 (FSCN1) in esophageal
squamous cell carcinoma [26]. In GC, FSCN1 also
might act as an oncogene and the high level of FSCN1
was significantly correlated with shorter survival time and
several aggressive pathological factors [27]. In addition,
FSCN1 mRNA was upregulated in accordance with miR-
133b down-regulation in GC patients [24]. However, the
tumor suppressor roles of miR-133b in GC and the de-
tailed mechanism are largely unknown.
In this study, we used Taqman probe stem-loop real-
time PCR to accurately measure the levels of miR-133b in
100 pairs of gastric cancer tissues and the adjacent non-
neoplastic tissues. We found that miR-133b was signifi-
cantly down-regulated in GC tissues and the lower level of
miR-133b in GC was significantly associated with a more
aggressive tumor phenotype. Re-introduction of miR-133b
to the GC cells could inhibit the cell proliferation, migra-
tion and invasion. The mechanism study indicated that
miR-133b directly targeted FSCN1 which functioned as an
oncogenic gene in GC cells. These results suggested that
miR-133b functioned its tumor suppressor’s role in GC
possibly through down-regulating FSCN1.
Methods
Patients and specimens
The human clinical samples were collected from surgical
specimens from 100 patients with gastric cancer at The
Military General Hospital of Beijing PLA. The study wasapproved by the ethical board of the hospital and the
ethical board of Beijing Jiaotong University. The corre-
sponding adjacent non-neoplastic tissues from the macro-
scopic tumor margin were isolated at the same time and
used as controls. Tumor and non-cancerous tissues were
confirmed histologically by haematoxylin and eosin (H&E)
staining. All samples were immediately snapped frozen in
liquid nitrogen and stored at −80°C until RNA extraction.Cell culture and transfections
The human gastric cancer cell lines, including HGC-27,
MGC-803, MKN-25 and SGC-7901 and normal human
gastric epithelium cells (GES) were propagated in DMEM
(Invitrogen) supplemented with 10% FCS at 37°C in 5%
CO2 cell culture incubator. 293 T cells were cultured in
DMEM medium supplemented with 10% FCS. miR-133b
mimics, scramble control mimic, FSCN1 siRNA and siRNA
control were obtained from Dharmacon (Austin, TX, USA)
and transfected with DharmFECT1 (Dharmacon, Austin,
TX, USA) in HGC-27 and MGC-803 cells at a final con-
centration of 50 nM.RNA extraction, cDNA synthesis, and real-time PCR assays
Total RNA was extracted from tissues and cells using
Trizol reagent (Invitrogen, CA, USA) according to the
manufacturer’s instructions. cDNA was synthesized by
M-MLV reverse transcriptase (Invitrogen) from 2 μg of
total RNA. A stem-loop RT primer was used for the re-
verse transcription of miR-133b. Quantitative RT-PCR
was performed in a Bio-Rad CFX96 real-time PCR Sys-
tem (Bio-Rad, CA, USA) using TaqMan probes (Applied
Biosystems, Foster City, CA, USA) according to the
manufacturer’ s instructions. The PCR conditions were
as follows: 95°C for 30 s, followed by 40 cycles of 95°C
for 5 s and 60°C for 34 s. The data were normalized
using the endogenous U6 snRNA. The 2-ΔΔCT method
was used in the analysis of PCR data. Primer sequences
are presented in Table 1.Cell proliferation assay and colony formation assay
To measure the effect of miRNA mimics or FSCN1
siRNA on cell proliferation, cells were incubated in 10%
CCK-8 (DOJINDO) diluted in normal culture media at
37°C until visual color conversion appears. Proliferation
rates were determined at day 1, 2, 3, 4 post-transfection,
and quantification was done on a microtiter plate reader
(Spectra Rainbow, Tecan) according to the manufactur-
er's protocol. Meanwhile, the mimic-transfected cells
were trypsinized and replated at 200 cells per well in 6-
well plates, cultured for 7 days, then fixed with metha-
nol and stained with 0.1% crystal violet in 20% methanol
for 15 min.
Table 1 Sequence of primers used in qRT-PCR and
constructs
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A wound-healing assay was performed to assess the cell
migration ability. An artificial wound was created on a
confluent cell monolayer 24 hours after transfection. Im-
ages were taken at 0, 24, 48 hours and percentage of open
wound was calculated.
HGC-27 and MGC-803 cells were seeded onto a
Matrigel-coated membrane matrix (BD Bioscience) present
in the insert of a 24 well culture plate. FBS was added to
the lower chamber as a chemoattractant. After 24 hours,
invasive cells located on the lower surface of chamber were
stained with the 0.1% crystal violet (Sigma) and counted.
Constructs and Luciferase assay
The reverse complementary sequence of miR-133b was
inserted into pMIR-reporter (Promega, WI, USA) to gen-
erate a reporter system (pMIR-133b) to detect mature
miRNA expression in 293 T cells. The 3′ UTR of the
human FSCN1 was PCR amplified and cloned into pMIR-
reporter downstream of the firefly luciferase gene to
generate the corresponding reporters. Mutations at the
miRNA binding site in these mRNA sequences were
created using bridging PCR. For miRNA targets ana-
lysis, the 293 T cells were co-transfected with 0.4 μg of
the reporter construct, 0.02 μg of pRL-TK vector, and 5
pmol of miRNA mimic or scramble controls. Cells were
harvested 48 h post-transfection and assayed with Dual
Luciferase Assay (Promega, WI, USA) according to manu-
facturer’s instructions. All transfection assays were carried
out in triplicates.
Western blotting
At the indicated times, MGC-803 cells and HGC-27 cells
were collected and the whole-cell lysate was extracted
using lysis buffer (0.05 M Tris, pH =7.5, 0.15 M NaCl, 2%NP-40) containing 200 lm Na3VO4, 200 mM NaF, 0.5 M
EDTA, proteinase inhibitors, for 30 min on ice. The
whole-cell lysate was quantified by BCA method ac-
cording to manufacturer’s instructions. Proteins were
separated by SDS-PAGE and then transferred to the
NC membrane for the subsequent immunoblot analysis.
The following antibodies were used for Western blot:
GAPDH (10494-1-AP, Proteintech), FSCN1 (14384-1-AP,
Proteintech).
Statistics
The comparison of miR-133b expression between gastric
cancer tissue and adjacent non cancer tissue was evaluated
by Independent Samples T test (two-tailed). Correlation of
miR-133b expression with patients’ clinicopathological var-
iables was evaluated by independent sample T-test (two-
tailed). P ≤0.05 was considered statistically significant.
Results
miR-133b is down-regulated in GC
To accurately analyze the expression of miR-133b in GC,
q-PCR using Taqman probes was conducted to measure
the levels of miR-133b. We firstly examined the expres-
sion of mature miR-133b in four human GC cell lines
(HGC-27, MGC-803, SGC-7901 and MKN-45) and a hu-
man gastric epithelium cell line (GES). The expression
level of miR-133b in the four GC cell lines was significant
lower than that in GES and the expression in MKN-45
cells was the lowest (Figure 1A). Subsequently, we mea-
sured the levels of miR-133b in 100 pairs of gastric cancer
tissues (C) and the adjacent non-neoplastic tissues (N).
The results of PCR showed that 57/100 (57%) of cases had
reduced levels of miR-133b in GC tissues compared with
the corresponding non-neoplastic tissues when the cutoff
was set up as 1.5 (Figure 1B). There were 19/100 (19%) of
cases had increased levels of miR-133b in gastric cancer
tissues compared with the adjacent normal tissues, 24/100
(24%) of cases in whom the expression of miR-133b in
gastric cancer tissues was unchanged when the cutoff
was set up as 1.5. The results also showed that the average
expression of miR-133b in gastric cancer samples was sig-
nificantly lower than that in the adjacent non-neoplastic
tissues (p < 0.01) (Figure 1C). Collectively, the data indi-
cated that miR-133b was significantly attenuated in tumor
tissues compared with adjacent normal tissues and might
act as a tumor suppressor in GC.
Low-level expression of miR-133b is associated with
aggressive phenotypes of GC
To further investigate the correlation between the expres-
sion of miR-133b and the clinicopathological characteris-
tics, the relative expression of miR-133b in 100 pairs of
gastric cancer tissues and adjacent normal tissues were
statistically analyzed. The clinicopathological features of
Figure 1 miR-133b is down-regulated in GC cells and in GC tissues. (A) The expression level of miR-133b in the four GC cell lines (HGC-27,
MGC-803, SGC-7901 and MKN-45) and a human gastric epithelium cell line (GES). Data are shown as mean + s.d. (n = 3); * indicates P-value <0.05;
** indicates P-value <0.01. (B) The relative expression of miR-133b in 100 pairs of GC tissues (C) and adjacent non-neoplastic tissues (N). (C)
Normalized expression of miR-133b in 100 pairs of GC and adjacent normal tissues. (D) The correlation of miR-133b expression with venous
invasion. (E) The correlation of miR-133b expression with tumor stages.
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Correlation analysis showed that low-level of miR-133b in
gastric cancer was associated with venous invasion (p <
0.05, Figure 1D) and a more aggressive tumor phenotype
(p < 0.05, stage I/II vs. III/IV) (Figure 1E). However, no
significant associations with age, gender, position, or
borrmann typing were observed. The correlation of
lower levels of miR-133b with the more aggressive
phenotype of gastric cancer strongly indicated that miR-
133b played important roles in gastric carcinogenesis.Re-introduction of miR-133b in GC cells can inhibit cell
growth and colony formation
To investigate the role of miR-133b in GC carcinogen-
esis, we re-introduced miR-133b mimics into two GC
cell lines, HGC-27 and MGC-803, in which miR-133b
was down-regulated. miR-133b was successfully overex-
pressed in these two cell lines which was confirmed by
q-PCR. As shown in Figure 2A and 2C, miR-133b was
overexpressed about 16 folds and 18 folds than the scram-
ble control or untreated cells in HGC-27 and MGC-803
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GC, the overexpression of miR-133b in both of the two
GC cell lines can inhibit GC cell proliferation significantly
as demonstrated by CCK-8 growth assay. The scramble
control had no effect on cell proliferation compared with
the untreated cells (Figure 2B, D). We also detected the ef-
fect of miR-133b on the colony formation ability of GCcells. The mimic-transfected GC cells were replated at low
density and maintained for 7 days. The overexpression of
miR-133b significantly decreased the colony number of
HGC-27 and MGC-803 cells, whereas the scramble control
had little effect on the colony number compared with the
untreated cells (Figure 2E, F). The results suggested that
miR-133b might act as a tumor suppressor in GC.
miR-133b can inhibit GC cell migration and invasion
We further assessed the effects of miR-133b on cell migra-
tion and invasion, which were the important determinants
of malignant progression and metastasis. A wound heal-
ing/scratch assay was used to evaluate the migration abil-
ity of HGC-27 and MGC-803 cells. Both of the two cell
lines treated with miR-133b mimic showed slow migration
rate compared with the scramble control or untreated
cells. The percentage of wound healing at 24 and 48 hours
after scratching was significantly decreased in GC cells
treated with miR-133b mimics (Figure 3A, B). Further-
more, we conducted a Matrigel cell invasion assay to as-
sess the role of miR-133b in regulating cell invasion. The
Matrigel cell invasion assay showed that overexpression of
miR-133b in the two GC cell lines dramatically decreased
the invaded cells compared with the scramble control and
untreated cells (Figure 3C, D). These results indicated that
miR-133b played important roles in regulating cell migra-
tion and invasiveness in gastric carcinogenesis.
Knockdown of miR-133b in GES cells can promote cell
proliferation and invasion
To further investigate the role of miR-133b in normal
gastric epithelium cells, we introduced miR-133b inhibi-
tors into GES cells. miR-133b was successfully reduced
in GES cells which was confirmed by q-PCR (Figure 4A).
Accompanied by the knockdown of miR-133b in GES
cells, cell proliferation was promoted significantly as dem-
onstrated by CCK-8 growth assay. The scramble control
had no effect on cell proliferation compared with the
untreated cells (Figure 4B). We also detected the effect of
miR-133b on GES cell invasion. The Matrigel cell invasion
assay showed that knockdown of miR-133b in GES cells
dramatically increased the invaded cells compared with
the scramble control and untreated cells (Figure 4C).
miR-133b targets FSCN1 in GC cells
We further dissected the mechanism by which miR-133b
functioned as a tumor suppressor in GC. miR-133b has
been reported to directly target oncogenic FSCN1 gene in
esophageal squamous cell carcinoma [26]. However, it was
still unknown whether miR-133b played its tumor sup-
pressor roles through targeting FSCN1 in GC.
miR-133b was predicted to bind to the 3′ -UTR region
of FSCN1 using two algorithms PicTar(http://pictar.m
dc-berlin.de/) and TargetScan(http://www.targetscan.org/)
Figure 2 Enforced expression of miR-133b suppresses cell proliferation and colony formation ability of GC cells. (A) Overexpression of
miR-133b in HGC-27 cells was confirmed by qRT-PCR. (B) The cell growth of HGC-27 cells at day 0, 1, 2, 3, 4 post transfection which was detected
by CCK-8 assay. Data are shown as mean ± s.d. (n = 3); ** indicates P-value <0.01. (C) Overexpression of miR-133b in MGC-803 cells was confirmed
by qRT-PCR. (D) The cell growth of MGC-803 cells at day 0, 1, 2, 3, 4 post transfection which was detected by CCK-8 assay. Data are shown as
mean ± s.d. (n = 3); ** indicates P-value <0.01; *** indicates P-value <0.001. (E) The colony number of HGC-27 cells per well in 6-well plates
cultured for 7 days. (F) The colony number of MGC-803 cells per well in 6-well plates cultured for 7 days.
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133b on FSCN1, we cloned the 3′ -UTR of FSCN1 into a
luciferase reporter construct (pMIR-reporter) meanwhilecloned nucleotide sequence complete complementary to
miR-133b as positive control (PC). Dramatic decrease of
luciferase activity of PC demonstrated that miR-133b
Figure 3 Enforced expression of miR-133b can inhibit GC cell migration and invasion. (A) The pictures of wound healing and the
percentages of open wound of HGC-27 cells at 0, 24, 48 hours after scratching. Data are shown as mean + s.d. (n = 3); ** indicates P-value <0.01.
(B) The pictures of wound healing and the percentages of open wound of MGC-803 cells at 0, 24, 48 hours after scratching. Data are shown as
mean + s.d. (n = 3); ** indicates P-value <0.01. (C) The invaded HGC-27 cells in the Matrigel transwell invasion assay. Data are shown as mean + s.d.
(n = 3); ** indicates P-value <0.01. (D) The invaded MGC-803 cells in the Matrigel transwell invasion assay. Data are shown as mean + s.d. (n = 3); **
indicates P-value <0.01.
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porter assay was convincing. The reporter assay also
showed that miR-133b repressed the luciferase activity
of FSCN1 3′ -UTR significantly compared with the scram-
ble control (Figure 5B). To test whether the repression
was dependent on the miRNA binding site, we con-
structed another luciferase reporter of FSCN1 3′ -UTR
in which the miRNA binding site in the 3′ -UTR was
mutated. The results indicated that mutation of the
miRNA binding sites in the FSCN1 3′ -UTR abrogatedthe reduction in luciferase activities which suggested
that the repression of miR-133b on FSCN1 3′ -UTR was
dependent on the miRNA binding site (Figure 5C). Con-
sistent with the reporter assay, we observed an evident de-
crease of FSCN1 protein in presence of miR-133b mimics
compared to scramble control in both of HGC-27 and
MGC-803 cells. Meanwhile, we also noticed that the ex-
pression level of FSCN1 in HGC-27 and MGC-803 cells
was higher than that in GES cells which was consistent
with low expression of miR-133b in GC cells (Figure 5D).
Figure 4 Knockdown of miR-133b in GES cells can promote cell proliferation and migration. (A) Inhibition of miR-133b in GES cells was
confirmed by qRT-PCR. (B) The cell growth of GES cells at day 0, 1, 2, 3, 4 post transfection which was detected by CCK-8 assay. Data are shown
as mean ± s.d. (n = 3); * indicates P-value <0.05;** indicates P-value <0.01. (C) The invaded GES cells in the Matrigel transwell invasion assay. Data
are shown as mean + s.d. (n = 3); ** indicates P-value <0.01.
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invasion
To investigate the role of FSCN1 in GC carcinogenesis,
we knocked down FSCN1 expression using siRNAs in
two GC cell lines, HGC-27 and MGC-803. As shown in
Figure 6A, the expression of FSCN1 was successfully
knocked down in both of the two cell lines which was
confirmed by Western blot. Knock down of FSCN1
attenuated GC cell proliferation significantly as demon-
strated by CCK-8 growth assay, whereas negative control
had no effect on cell proliferation compared with the
untreated cells (Figure 6B). We also detected the effectof FSCN1 in regulating cell invasion using the Matrigel
cell invasion assay. The results showed that repressed
FSCN1 in the two GC cell lines dramatically decreased
the invaded cells compared with the negative control
and untreated cells (Figure 6C, D). Finally, we examined
the protein level of FSCN1 in 6 randomly selected clin-
ical samples in which miR-133b was down-regulated in
their GC tissues. Among the total 6 GC patients we
investigated, there were five cases in which FSCN1 was
up-regulated along with the down-regulation of miR-
133b in GC tissues indicating that miR-133b suppress
the expression of FSCN1 in these patients (Figure 6E).
Figure 5 FSCN1 is a direct target of miR-133b in GC cells. (A) Schematic representation of FSCN1 3′ UTR showing putative miR-133b
binding site. (B) Relative luciferase activity of FSCN1 3′ UTR reporter constructs in 293 T cells. Data are shown as mean + s.d. (n = 3); * indicates
P-value <0.05, ** indicates P-value <0.01. (C) Relative luciferase activity of wild type and mutated FSCN1 3′ UTR constructs in 293 T cells. Data are
shown as mean + s.d. (n = 3); * indicates P-value <0.05, ** indicates P-value <0.01. (D) Western blot analysis of FSCN1 expression in HGC-27 and
MGC-803 cells transfected with scramble control or miR-133b mimics; FSCN1 expression level in GES, HGC-27 and MGC-803 cells.
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ant roles in GC as an oncogene and miR-133b regulated
GC cell proliferation, migration and invasion through
targeting FSCN1.
Discussion
In this study, we investigated the expression of miR-133b
in 100 patients with gastric cancer and dissected the roles
and mechanisms of miR-133b in GC carcinogenesis. We
found that miR-133b was significantly down-regulated in
GC tissues and the low expression of miR-133b was
associated with the more aggressive phenotypes of GC.
Re-introduction of miR-133b into GC cells can obviously
inhibit GC cell proliferation, migration and invasion and
the tumor suppressor roles of miR-133b in GC was par-
tially through targeting oncogenic FSCN1. These results
suggested that miR-133b can be developed as a new diag-
nostic marker or therapeutic target for GC.
The aberrant expression of miRNAs in GC has been
studied in recent years and a total of 139 differentially
expressed miRNAs were reported in thirteen miRNA ex-
pression profiling studies that compared GC tissues with
neighbouring noncancerous or normal gastric tissues
[28]. miR-21, miR-18a, miR-17 and miR-20a were themost frequently reported to be up-regulated in GC tis-
sues [29-36]. Whereas, miR-375 and miR-378 were often
detected to be down-regulated in GC tissues [29-32,34].
Meanwhile, various miRNAs have been shown to func-
tion as either tumor suppressors (inhibiting oncogenic
potential) or oncogenes (promoting oncogenic potential)
in GC. For example, miR-106b-25 cluster was reported
to play a key role in TGF-β1 mediated tumor suppressor
pathway in GC and the upregulation of these miRNAs
impairs the TGF-β1 pathway, interfering with the ex-
pression of p21 [37]. The oncogenic cluster miR-221-222
can suppress expression of cyclin-dependent kinase inhib-
itors (p21, p27, p57) in GC, thus promoting GC cell pro-
liferation [38]. miR-148a also can regulate the cell cycle
progression through targeting p27 and knock down of
miR-148a can inhibit GC cell proliferation [39]. miRNA
are also indicated to play important roles in multidrug re-
sistance in GC. Because miRNAs are small, stable against
degradation, easy to be detected and easy to deliver, these
aberrant expression miRNAs in GC are attractive as
potential biomarkers and new targets for gastric cancer
therapy. However, the potential diagnostic and therapeutic
roles of these miRNAs in more clinical samples are just at
the beginning and need to be explored further.
Figure 6 Knock down of FSCN1 can inhibit GC cell growth and invasion. (A) Western blot analysis of FSCN1 expression in HGC-27 and
MGC-803 cells transfected with negative control or FSCN1 siRNAs. (B) The cell growth of HGC-27 and MGC-803 cells at day 0, 1, 2, 3, 4 post
transfection which was detected by CCK-8 assay. Data are shown as mean + s.d. (n = 3); * indicates P-value <0.05. ** indicates P-value <0.01.
*** indicates P-value <0.001. (C) The invaded HGC-27 cells in the Matrigel transwell invasion assay. Data are shown as mean + s.d. (n = 3);
** indicates P-value <0.01. (D) The invaded MGC-803 cells in the Matrigel transwell invasion assay. Data are shown as mean + s.d. (n = 3); ** indicates
P-value <0.01. (E) Western blot analysis of FSCN1 expression in 6 pairs of GC tissues (C) and the adjacent non-neoplastic tissues (N).
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GC, miR-133b was firstly reported to be down-regulated
in GC tissues in three patients by microRNA microarray
assay [23]. Subsequently, the level of miR-133b wasinvestigated in 19 cases of gastrointestinal stromal tumor
(GIST) and miR-133b was reported to be downregulated
in high-grade GISTs suggesting it might have an import-
ant role in the progression of GIST [24]. A recent study
Guo et al. Journal of Experimental & Clinical Cancer Research 2014, 33:99 Page 11 of 12
http://www.jeccr.com/content/33/1/99also identified miR-133b levels in 12 pairs of GC tissue
samples and found that miR-133b expression was down-
regulated in 11/12 of the tested GC tissues compared with
matched nontumor tissues [25]. In our study, we investi-
gated the expression of miR-133b in large numbers of
patients with gastric cancer firstly. The significant down-
regulation of miR-133b in GC tissues was consistent
with the previous report and also hinted that it can be
developed as a potential biomarker for GC diagnosis.
Furthermore, we also found that low-level expression of
miR-133b was associated with aggressive phenotypes of
gastric cancer. In addition, miR-133b has been reported
to suppress GC cell proliferation through targeting
FGFR1 [25]. We found that miR-133b not only can
inhibit the GC cell proliferation but also could suppress
the GC cell migration and invasion. To further investigate
the tumor suppressor role of miR-133b and the detailed
mechanism in vivo will be helpful for understanding the
essential role of miR-133b in gastric cancer progression.
FSCN1 encodes a member of fascin family of actin-
binding proteins. Fascin proteins organize F-actin into
parallel bundles, and are required for the formation of
actin-based cellular protrusions. FSCN1 plays important
roles in cell migration, motility, adhesion and cellular in-
teractions and act as an oncogene in multiple types of can-
cer by increasing cell motility [40]. Knockdown of fascin1
expression have been reported to be able to suppress the
proliferation and metastasis of MKN45 gastric cancer cells
[41]. Fascin-1 was also involved in Galectin-3, a beta-
galactoside-binding protein, mediated gastric cancer cell
motility increasement [42]. Moreover, higher expression of
fascin-1 was also correlated directly with more-advanced
cancer stages (TNM) and inversely with survival rates in
gastric adenocarcinomas [43]. miR-133b has been re-
ported to directly regulate FSCN1 in esophageal squamous
cell carcinoma [26]. In our study, we indicated that FSCN1
was also a direct target of miR-133b in GC cells. We also
demonstrated that knock down of FSCN1 can inhibit GC
cell growth and invasion suggesting its oncogenic roles in
GC. So we concluded that miR-133b suppressed GC cell
proliferation, migration and invasion through targeting
FSCN1. Moreover, the inverse correlation of FSCN1 and
miR-133b has been improved in 19 cases of GIST. These
studies suggested that the down-regulation of miR-133b
and the resulting elevated FSCN1 level played critical role
in GC carcinogenesis.
Conclusion
In summary, we demonstrated the significant down-
regulation of miR-133b in large numbers of GC patients
and the lower expression of miR-133b in high grade GC
patients. We also dissected the tumor suppressor roles
of miR-133b in GC cells and found that it was partially
through targeting oncogenic FSCN1.Consent
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